Received Jul 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
Currently Diagnose for Left Cervical lymph node Adenocarcinoma; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A patient (age and gender not provided) received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Endometrial Carcinoma" (unspecified if ongoing); "Chemo therapy" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: ADENOCARCINOMA METASTATIC (medically significant), outcome "unknown", described as "Currently Diagnose for Left Cervical lymph node Adenocarcinoma". Clinical course: Currently Diagnose for Left Cervical lymph node Adenocarcinoma after patient Endometrial Carcinoma Chemotherapy. patient need more information, if how can patient be under study of patient p16 ,p53 DNA .with this, patient was thinking ,that the COVID vaccine RNA has something to do that changes my Genes and creating this new mutations of Cancer being a Post Menopausal. Hope more research on the way. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Chemotherapy; Endometrial carcinoma